J. Bradley Layton, PhD, FISPE

Director, Epidemiology
RTI Health Solutions
Research Triangle Park, North Carolina, United States

Bradley Layton, PhD, is a Director of Epidemiology at RTI Health Solutions. He has considerable experience in the design, conduct, analysis, and reporting of epidemiologic studies and has over 10 years of experience in the field of pharmacoepidemiology. His experience and publications span a wide range of substantive areas, including renal, cardiovascular, men's health, vaccines, and pregnancy, and incorporate multidatabase and multinational studies. Dr. Layton also has experience with epidemiologic methods, lecturing to clinical and public health audiences about observational study design, large database utilization, and propensity score analysis. Dr. Layton received his master's and doctorate degrees in epidemiology from the Department of Epidemiology in the Gillings School of Global Public Health, University of North Carolina at Chapel Hill, focusing in pharmacoepidemiology with an emphasis in renal disease. Prior to joining RTI-HS, he was a member of the faculty in the Pharmacoepidemiology Program in the University of North Carolina Department of Epidemiology, where he accrued vast experience leading studies that utilized secondary health care data sets to evaluate pharmaceutical use, safety, and effectiveness, and he is currently an adjunct assistant professor at the University of North Carolina. As a faculty member, he organized and taught in several workshops and training courses for epidemiologists in pharmaceutical companies, as well as a set of methods workshops for epidemiologists at the Food and Drug Administration. Dr. Layton also is an active member of the International Society of Pharmacoepidemiology, having served on the Scientific Program Committee since 2014 as the chair of the spotlight poster sessions.

RTI Health Solutions (Employment)

Presentation(s):

• Considerations of Misclassification and Confounding on COVID-19 Vaccines Effectiveness Studies - A Vaccine SIG Endorsed Symposium

  Friday, August 26, 2022
  3:30 PM – 5:00 PM CEST

• Risk of Mortality Associated with Pimavanserin Compared with Atypical Antipsychotics in Patients with Parkinson's Disease—related Psychosis

  Saturday, August 27, 2022
  9:15 AM – 9:30 AM CEST

• Updates from the COVID-19 Pharmacoepidemiological Battlefield: Recent Victories and Battles Ahead [Plenary]

  Saturday, August 27, 2022
  10:00 AM – 11:30 AM CEST

• Lightning Session 2

  Saturday, August 27, 2022
  1:00 PM – 2:30 PM CEST